Home > Healthcare > Pharmaceuticals > Finished Drug Form > Vaginitis Therapeutics Market

Vaginitis Therapeutics Market Analysis

  • Report ID: GMI7213
  • Published Date: Oct 2023
  • Report Format: PDF

Vaginitis Therapeutics Market Analysis

Vaginitis Therapeutics Market, By Disease Type, 2021 - 2032 (USD Billion)

To understand key trends  
Download Free Sample
 

Based on disease type, the market is classified into bacterial vaginosis, candidiasis, trichomoniasis, and other disease type. In the year 2022, bacterial vaginosis segment dominated the market with a substantial share of 43.6%.
 

  • Bacterial vaginosis is the most prevalent vaginal infection among women of reproductive age. Its widespread occurrence means a large patient population requiring treatment. The disease often recurs after treatment, necessitating repeated or extended courses of therapy. This recurrence leads to a consistent demand for therapeutics, both prescription and over the counter, to manage the condition.
     
Vaginitis Therapeutics Market Revenue Share, By Drug Class, (2022)

To understand key market trends  
Download Free Sample
 

Based on drug class, the vaginitis therapeutics market is divided into anti-fungal, anti-bacterial, anti-protozoal, and other drug class. The anti-bacterial segment is expected to reach USD 3.5 billion by 2032.
 

  • Anti-bacterial drugs are effective in treating various cases of vaginitis, as they target the bacteria causing the infection. Metronidazole and clindamycin, the most prescribed antibiotics have been found to be effective in clinical studies, leading to their widespread use.
     
  • Moreover, healthcare providers often prescribe these drugs as the first line of treatment for suspected bacterial infections, as well as for trichomoniasis. Therefore, the established efficacy and safety of these drugs influence physician prescribing patterns, leading to a higher utilization rate in the market and is expected to dominate the market throughout the forecast period.
     

Based on route of administration, the vaginitis therapeutics market is segmented into oral and topical. The topical segment accounted for USD 2.5 billion in 2022.
 

  • The highest market share can be attributed to their targeted delivery, minimized systemic absorption, versatility, and effectiveness. Also, these products are available over the counter without a prescription. This accessibility encourages self-treatment and immediate use, especially for common conditions like yeast infections.
     
  • Furthermore, topical treatments often include soothing agents that provide immediate relief from symptoms such as itching, burning, and irritation. This relief and enhanced comfort contribute to patient satisfaction and drive the popularity of topical therapeutics and thus, is expected to boost the market progress.
     

Based on mode, the market is bifurcated into over the counter (OTC) and prescription mode. OTC segment dominated the market with a substantial share of 63.5%.
 

  • Many vaginal conditions, such as yeast infections and bacterial vaginosis, are common and can often be self-diagnosed by patients based on recognizable symptoms. OTC products provide a convenient solution for individuals experiencing these common conditions without the need for a doctor's visit or prescription. Such benefits associated with OTC mode is expected to spur the growth of the segment.
     

Based on distribution channel, the vaginitis therapeutics market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Hospital pharmacy segment dominated the market with USD 1.6 billion in 2022.
 

  • Hospitals deal with a wide array of medical conditions, including severe or complex vaginal infections that require specialized prescription medications. Such specialized treatments are often dispensed and managed by hospital pharmacies.
     
  • Furthermore, patients undergoing gynecological surgeries or procedures, such as hysterectomies, may require specific vaginal therapeutics post-surgery. Therefore, hospital pharmacies provide these medications to patients during their recovery period.
     
North America Vaginitis Therapeutics Market Size, 2020 – 2032 (USD Million)

To understand regional trends  Download Free Sample
 

The North America vaginitis therapeutics market is expected to grow at 7.3% during the analysis period.
 

  • North America has a significant aging population. The population are more susceptible to vaginal infections due to hormonal changes, making them a key demographic for vaginal therapeutics. The higher prevalence of menopausal and postmenopausal women in North America further increases the demand for treatments addressing vaginal health issues.
     
  • Additionally, the region leads in medical research and technological innovations, advanced diagnostic tools, research initiatives, and innovative therapies for vaginal health are more readily available, thereby contributing to the growth of the market.
Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Vaginitis therapeutics industry size was USD 3.6 billion in 2022 and is expected to reach USD 7.3 billion by 2032 due to the rising prevalence of vaginal infections, growing awareness pertaining to women’s health and the increasing availability of effective treatments worldwide.

The bacterial vaginosis disease type segment held 43.6% share of the vaginitis therapeutics industry in 2022 and is expected to register a significant CAGR from 2023-2032 on account of it being the most prevalent vaginal infection among women of reproductive age.

North America vaginitis therapeutics industry is expected to grow at 7.3% CAGR from 2023-2032 owing to a high prevalence of menopausal and postmenopausal women in the region.

Pfizer, Inc., Merck & Co., Novartis AG, Bayer AG, Lupin Pharmaceuticals, Inc., Sanofi SA, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceuticals Pvt Ltd, Cipla Ltd, and Takeda Pharmaceuticals, are some of the major market worldwide.

Vaginitis Therapeutics Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 11
  • Tables & Figures: 316
  • Countries covered: 9
  • Pages: 170
 Download Free Sample